

Consolidated Financial Results for the Three Months Ended March 31, 2022 [IFRS]

May 12, 2022

Company name: PeptiDream Inc. Tokyo Stock Exchange
 Stock code: 4587 URL <https://www.peptidream.com/>
 Representative: Patrick C. Reid, President & Chief Executive Officer
 Inquiries: Yuko Okimoto, Head of Investor Relations
 Scheduled filing date of quarterly securities report: May 16, 2022
 Scheduled starting date of dividend payments: —
 Supplementary briefing materials on quarterly financial results: No
 Explanatory meeting on quarterly financial results: No

TEL: +81-44-223-6612

(Amounts of less than one million yen are rounded down)

1. Consolidated Financial Results for the Three Months Ended March 31, 2022 (January 1, 2022 to March 31, 2022)

(1) Consolidated operating results (% indicates changes from the previous corresponding period)

	Revenue		Operating profit		Profit before tax		Profit attributable to owners of parent		Total comprehensive income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Three Months ended March 31, 2022	419	(71.6)	(1,166)	-	(1,123)	-	(829)	-	(681)	-
Three Months ended March 31, 2021	1,477	-	(5)	-	(39)	-	(221)	-	(184)	-

	Basic earnings per share		Diluted earnings per share	
	Yen	Yen	Yen	Yen
Three Months ended March 31, 2022	(6.39)	(6.39)	(6.39)	(6.39)
Three Months ended March 31, 2021	(1.74)	(1.74)	(1.74)	(1.74)

(2) Consolidated financial position

	Total assets	Net assets	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
	Million yen	Million yen	Million yen	%
As of March 31, 2022	52,104	24,675	24,675	47.4
As of December 31, 2021	27,034	25,350	25,350	93.8

2. Payment of Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year ended December 31, 2021	-	0.00	-	0.00	0.00
Fiscal Year ending December 31, 2022	-	-	-	-	-
Fiscal Year ending December 31, 2022 (forecast)	-	0.00	-	0.00	0.00

(Note) Revisions to the dividend forecast announced most recently: No

3. Consolidated Financial Forecasts for the Fiscal Year Ending December 31, 2022 (January 1, 2022 to December 31, 2022)

	Revenue	Operating profit	Profit before tax	Profit attributable to owners of parent	Basic earnings per share
	Million yen / %	Million yen / %	Million yen / %	Million yen / %	yen
Fiscal Year ending December 31, 2022	24,500	-	-	-	-

(Note) Revisions to the consolidated financial forecast announced most recently: Yes

The Company is in the process of examining the impact of the March 28, 2022 acquisition of PDRadiopharma Inc. on its financial results, such as the purchase price allocation, and plans to disclose the consolidated financial forecasts for the fiscal year ending December 31, 2022 for items other than revenue as soon as they are finalized.

Non-consolidated financial forecasts, which form the basis for preparing consolidated financial forecasts, remain unchanged from the financial forecasts disclosed in the FY2021 financial results on February 9, 2022.

[Notes]

Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in change in scope of consolidation) : Yes

Newly included : 1 company (PDRadiopharma Inc.)

Excluded : –

(2) Changes in accounting policies and changes in accounting estimates

1) Changes in accounting policies required by IFRS : None

2) Changes in accounting policies due to other reasons : None

3) Changes in accounting estimates : None

(3) Number of shares issued (common stock)

1) Number of shares issued at the end of the period (including treasury stock)

2) Number of treasury stock at the end of the period

3) Average number of shares during the period

As of March 31, 2022	130,010,400 shares	As of December 31, 2021	130,010,400 shares
As of March 31, 2022	183,005 shares	As of December 31, 2021	182,964 shares
Three months ended March 31, 2022	129,827,419 shares	Three months ended March 31, 2021	127,136,706 shares

(Note) The number of treasury shares at the end of the period includes shares in the Company held by the Custody Bank of Japan, Ltd. (Trust Account E) (182,800 shares as of December 31, 2021 and 182,800 shares as of March 31, 2022). In addition, the shares in the Company held by the Custody Bank of Japan, Ltd. (Trust Account E) are included in treasury shares excluded from calculating the average number of shares during the period (193,600 shares for the three months ended March 31, 2021 and 182,800 shares for the three months ended March 31, 2022).

* Quarterly financial results reports are not required to be subjected to quarterly review by a certified public accountant or an audit firm

* Explanation on the appropriate use of operating forecasts and other special instructions

(Caution regarding forward-looking statements)

Financial forecasts and other statements regarding the future presented in these materials are based on information currently available and certain assumptions deemed to be reasonable and are not meant to be taken as commitment of the Company to achieve such results. Actual performance may differ substantially due to various factors.

(Adoption of International Financial Reporting Standards (IFRS))

IFRS is applied from the three months ended March 31, 2022, in place of the Japanese standard. Accordingly, the figures for the same period of the previous fiscal year and the previous fiscal year are also calculated in accordance with IFRS for comparison purposes.